logo

For the Inventor, By the Inventor

Torrance, CA, United States of America

Cho-Lea Tso

This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: University of California. Active years: 2009-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Cho-Lea Tso. Retrieved from https://idiyas.com/inventor/cho-lea-tso

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 25.0

Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 29(Granted Patents)


Company Filing History:

goldMedal4 out of 16,008 
 
University of California
 patents

Years Active: 2009-2018

Loading Chart...
4 patents (USPTO):Explore Patents
1. 10035981 - Kidney-specific tumor vaccine directed against kidney tumor antigen G-250 (2018-07-31),
2. 9409965 - Kidney-specific tumor vaccine directed against kidney tumor antigen G-250 (2016-08-09),
3. 8741306 - Kidney specific tumor vaccine directed against kidney tumor antigen G-250 (2014-06-03),
4. 7572891 - Kidney-specific tumor vaccine directed against kidney tumor antigen G-250 (2009-08-11),

Title: Cho-Lea Tso: Innovator in Kidney Cancer Immunotherapy

Introduction

Cho-Lea Tso is a prominent inventor based in Torrance, CA (US), known for his significant contributions to the field of immunotherapy for kidney cancer. With a total of 4 patents, Tso has focused on developing innovative solutions aimed at improving treatment outcomes for patients suffering from renal cell cancers.

Latest Patents

One of Tso's latest patents is a kidney-specific tumor vaccine directed against the kidney tumor antigen G-250. This invention provides an anti-cancer immunogenic agent that elicits an immune response specifically directed against renal cell cancers expressing the G250 antigenic marker. The preferred immunogenic agents comprise a chimeric molecule that includes a kidney cancer-specific antigen (G250) attached to a granulocyte-macrophage colony-stimulating factor (GM-CSF). These agents are useful in various treatment modalities, including protein vaccination, DNA vaccination, and adoptive immunotherapy.

Career Highlights

Cho-Lea Tso is affiliated with the University of California, where he continues to advance his research in cancer immunotherapy. His work has garnered attention for its potential to revolutionize treatment approaches for kidney cancer patients.

Collaborations

Tso collaborates with notable professionals in the field, including Arie S Belldegrun, who is also recognized for her contributions to cancer research and treatment.

Conclusion

Cho-Lea Tso's innovative work in developing targeted immunotherapies for kidney cancer exemplifies the potential of scientific research to improve patient outcomes. His contributions are paving the way for new treatment options in the fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…